With its complex structure and the breadth of ocular disorders, the eye presents unique challenges to drug discovery. Cambridge Healthtech Institute’s fourth annual Targeting Ocular Disorders conference provides a platform to discuss novel targets and disease pathways, the latest drug delivery methods, and the most promising emerging therapies. A special focus will be on gene therapy, stem cell therapies, and treatments outside of the well-established anti-VEGF therapies. The event will cover a broad range of diseases including but not limited to glaucoma, wet and dry age‐related and diabetic macular degeneration, retinopathy and retinitis pigmentosa.

Preliminary Agenda

Gene Therapy for Retinal Diseases

Gene Therapy for Retinal Diseases

Abraham Scaria, Ph.D., Senior Scientific Director, Ophthalmology, Genzyme, a Sanofi Company

AAV2 Rep-1 Gene Therapy in the Treatment of Choroideremia

David Fellows, CEO, NightstaRx

Novel Targets and Disease Pathways Outside of Conventional Anti-VEGF Monotherapies

Dual Antagonism of Platelet Derived Growth Factor (Fovista®) and Vascular Endothelial Growth Factor (Ranibizumab) in Neovascular Age-Related Macular Degeneration (nAMD)

Thomas A. Ciulla, M.D., MBA, Vice President, Clinical Strategy, Ophthotech

Squalamine Lactate Ophthalmic Solution: A Topical Approach to Combination Therapy for AMD

Jason Slakter, CEO, Ohr Pharmaceutical, Inc.

Treating Diabetic Eye Disease via Activation of Tie2 by AKB-9778: Results of a Phase II Clinical Study

Mitchell Brigell, Ph.D., Vice President, Clinical Development, Aerpio Therapeutics

Single Domain Antibodies against CXCR4 as a Potential Therapy in Retinal Vascular Disease

Mick Foley, Ph.D., CSO, Biochemistry, AdAlta, Australia

Stem Cells for Ocular Disorders

Translating Genomics and Stem Cell Technology into Therapy for Major Blinding Diseases

Kang Zhang, M.D., Ph.D., Professor, Ophthalmology, Chief, Ophthalmic Genetics, University of California, San Diego

Palucorcel for the Treatment of Geographic Atrophy in AMD

James S. Baldassarre, M.D., Head, Clinical Development, Janssen

Stem Cell-Derived Retinal Pigment Epithelium for Treatment of Retinal Degeneration

Irina Klimanskaya, Senior Director, Stem Cell Biology, Ocata Therapeutics, an indirect wholly-owned subsidiary of Astellas Pharma Inc.

Innovative Drug Delivery Methods

Current Trends in Ocular Drug Delivery

Ken Mandell, President and CEO, LayerBio, Inc.

A Novel Crosslinked Hyaluronic Acid (CMHA-S) Platform for Treating Ocular Diseases

Barbara Wirostko, CMO, Ophthalmology, Jade Therapeutics


For questions or suggestions about the meeting, please contact:
Lee Yuan
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5404
E: lyuan@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Speaker Proposals Now Being Accepted

Part Of DOT


The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager